ERBB2 and neoplasm: In addition, BLI confirmed sustained inhibition of tumor engraftment in all ERBB2-CAR CIK cell-treated mice (n = 8), whereas mice treated with WT CIK cells only transiently responded, but ultimately progressed in 2 of 6 (33%) cases (Figures 2D,E, WT, n = 6 and ERBB2-CAR CIK, n = 8).